CN102229589A - 作为金属蛋白酶抑制剂的n-{4′-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物 - Google Patents

作为金属蛋白酶抑制剂的n-{4′-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物 Download PDF

Info

Publication number
CN102229589A
CN102229589A CN201110103041XA CN201110103041A CN102229589A CN 102229589 A CN102229589 A CN 102229589A CN 201110103041X A CN201110103041X A CN 201110103041XA CN 201110103041 A CN201110103041 A CN 201110103041A CN 102229589 A CN102229589 A CN 102229589A
Authority
CN
China
Prior art keywords
compound
alkyl
acceptable salt
ring
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201110103041XA
Other languages
English (en)
Chinese (zh)
Inventor
莫里斯.R.V.芬利
戴维.沃特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102229589(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN102229589A publication Critical patent/CN102229589A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201110103041XA 2003-06-27 2004-06-23 作为金属蛋白酶抑制剂的n-{4′-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物 Pending CN102229589A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922-1 2003-06-27
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2004800182447A Division CN1812974B (zh) 2003-06-27 2004-06-23 作为金属蛋白酶抑制剂的n-{‘4-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物

Publications (1)

Publication Number Publication Date
CN102229589A true CN102229589A (zh) 2011-11-02

Family

ID=27656653

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201110103041XA Pending CN102229589A (zh) 2003-06-27 2004-06-23 作为金属蛋白酶抑制剂的n-{4′-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物
CN2004800182447A Expired - Fee Related CN1812974B (zh) 2003-06-27 2004-06-23 作为金属蛋白酶抑制剂的n-{‘4-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2004800182447A Expired - Fee Related CN1812974B (zh) 2003-06-27 2004-06-23 作为金属蛋白酶抑制剂的n-{‘4-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物

Country Status (33)

Country Link
US (1) US7485644B2 (cg-RX-API-DMAC7.html)
EP (1) EP1644340B1 (cg-RX-API-DMAC7.html)
JP (1) JP4701167B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060026440A (cg-RX-API-DMAC7.html)
CN (2) CN102229589A (cg-RX-API-DMAC7.html)
AR (1) AR044931A1 (cg-RX-API-DMAC7.html)
AT (1) ATE414063T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004251104B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411929A (cg-RX-API-DMAC7.html)
CA (1) CA2529468A1 (cg-RX-API-DMAC7.html)
CO (1) CO5650254A2 (cg-RX-API-DMAC7.html)
CY (1) CY1108757T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004017733D1 (cg-RX-API-DMAC7.html)
DK (1) DK1644340T3 (cg-RX-API-DMAC7.html)
ES (1) ES2315675T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20090009T3 (cg-RX-API-DMAC7.html)
IL (1) IL172615A0 (cg-RX-API-DMAC7.html)
IS (1) IS8257A (cg-RX-API-DMAC7.html)
MX (1) MXPA05013460A (cg-RX-API-DMAC7.html)
MY (1) MY138680A (cg-RX-API-DMAC7.html)
NO (1) NO20060444L (cg-RX-API-DMAC7.html)
NZ (1) NZ544208A (cg-RX-API-DMAC7.html)
PL (1) PL1644340T3 (cg-RX-API-DMAC7.html)
PT (1) PT1644340E (cg-RX-API-DMAC7.html)
RU (1) RU2351595C2 (cg-RX-API-DMAC7.html)
SA (1) SA04250224B1 (cg-RX-API-DMAC7.html)
SE (1) SE0301922D0 (cg-RX-API-DMAC7.html)
SI (1) SI1644340T1 (cg-RX-API-DMAC7.html)
TW (1) TW200524898A (cg-RX-API-DMAC7.html)
UA (1) UA81491C2 (cg-RX-API-DMAC7.html)
UY (1) UY28387A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005000822A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200510458B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
AU2006307939B2 (en) * 2005-10-26 2012-03-29 Merck Serono Sa Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8765814B2 (en) * 2010-07-08 2014-07-01 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934094T2 (de) * 1998-01-30 2007-06-06 Darwin Discovery Ltd., Slough N-hydroxyformamid-derivate
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
ES2281346T3 (es) * 1999-06-04 2007-10-01 Astrazeneca Ab Inhibidores de metaloproteinasas.
EP1261590B1 (en) 2000-02-21 2012-04-11 AstraZeneca AB Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
CA2483314A1 (en) * 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
DE602004017178D1 (de) * 2003-06-19 2008-11-27 Ucb Pharma Sa Hydroxamatsulfonamide als inhibitoren von cd23-shedding

Also Published As

Publication number Publication date
EP1644340A1 (en) 2006-04-12
CN1812974A (zh) 2006-08-02
CA2529468A1 (en) 2005-01-06
SI1644340T1 (sl) 2009-02-28
IS8257A (is) 2006-01-23
DK1644340T3 (da) 2009-02-02
JP4701167B2 (ja) 2011-06-15
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
DE602004017733D1 (de) 2008-12-24
MY138680A (en) 2009-07-31
WO2005000822A1 (en) 2005-01-06
SE0301922D0 (sv) 2003-06-27
HK1086835A1 (en) 2006-09-29
AR044931A1 (es) 2005-10-12
AU2004251104A1 (en) 2005-01-06
ATE414063T1 (de) 2008-11-15
US20070197542A1 (en) 2007-08-23
AU2004251104B2 (en) 2008-05-08
IL172615A0 (en) 2006-04-10
PL1644340T3 (pl) 2009-04-30
US7485644B2 (en) 2009-02-03
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
JP2007516164A (ja) 2007-06-21
CY1108757T1 (el) 2014-04-09
TW200524898A (en) 2005-08-01
RU2005141058A (ru) 2006-07-27
KR20060026440A (ko) 2006-03-23
HRP20090009T3 (en) 2009-02-28
BRPI0411929A (pt) 2006-08-15
RU2351595C2 (ru) 2009-04-10
MXPA05013460A (es) 2006-03-09
EP1644340B1 (en) 2008-11-12
ES2315675T3 (es) 2009-04-01
CO5650254A2 (es) 2006-06-30
UY28387A1 (es) 2005-01-31
CN1812974B (zh) 2011-06-29
PT1644340E (pt) 2009-01-02
UA81491C2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
CN101541789B (zh) 用作基质金属蛋白酶抑制剂的乙内酰脲衍生物
JP5527739B2 (ja) 好中球エラスターゼ活性の阻害が有益である疾患または状態の処置のための２−ピリドン誘導体
JP2009536196A (ja) 好中球エラスターゼ活性の阻害が有益である疾患または状態の処置のための２−ピリドン誘導体
CN101080402B (zh) 用作金属蛋白酶抑制剂的乙内酰脲衍生物
ZA200706671B (en) Quinazoline derivatives as tyrosine kinase inhibitors
CN101384582A (zh) 作为c-c趋化因子（ccr2b和ccr5）的拮抗剂用于治疗炎性疾病的哌嗪类化合物
CN1812974B (zh) 作为金属蛋白酶抑制剂的n-{‘4-取代的哌嗪-1-磺酰基甲基烷基}-n-羟基甲酰胺化合物
HK1086835B (en) N-[({'4-substituted piperazine-1-yl}sulfonylmethyl)alkyl]-n-hydroxyformamide compounds as metalloproteinase inhibitors
HK1108435B (en) Hydantoin derivatives useful as metalloproteinase inhibitors
HK1131148A (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111102